Value-based genomics

Jun Gong; Kathy Pan; Marwan Fakih; Sumanta Pal; Ravi Salgia

doi:10.18632/oncotarget.24353

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Value-based genomics

Jun Gong, Kathy Pan, Marwan Fakih, Sumanta Pal and Ravi Salgia _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:15792-15815. https://doi.org/10.18632/oncotarget.24353

Metrics: PDF 2548 views | HTML 32410 views | ?

Abstract

Jun Gong1, Kathy Pan2, Marwan Fakih1, Sumanta Pal1 and Ravi Salgia3

1Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA

2Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA

3Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Correspondence to:

Ravi Salgia, email: [email protected]

Keywords: next-generation sequencing; precision oncology; pathways; cost-effectiveness; value-based care

Received: November 30, 2017 Accepted: January 19, 2018 Epub: January 30, 2018 Published: March 20, 2018

ABSTRACT

Advancements in next-generation sequencing have greatly enhanced the development of biomarker-driven cancer therapies. The affordability and availability of next-generation sequencers have allowed for the commercialization of next-generation sequencing platforms that have found widespread use for clinical-decision making and research purposes. Despite the greater availability of tumor molecular profiling by next-generation sequencing at our doorsteps, the achievement of value-based care, or improving patient outcomes while reducing overall costs or risks, in the era of precision oncology remains a looming challenge. In this review, we highlight available data through a pre-established and conceptualized framework for evaluating value-based medicine to assess the cost (efficiency), clinical benefit (effectiveness), and toxicity (safety) of genomic profiling in cancer care. We also provide perspectives on future directions of next-generation sequencing from targeted panels to whole-exome or whole-genome sequencing and describe potential strategies needed to attain value-based genomics.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24353

Publication Alerts

Reviews:

Value-based genomics

Abstract